Marcello Allegretti
Marcello Allegretti
Dompé Farmaceutici spa
Verified email at
Cited by
Cited by
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury
R Bertini, M Allegretti, C Bizzarri, A Moriconi, M Locati, G Zampella, ...
Proceedings of the National Academy of Sciences 101 (32), 11791-11796, 2004
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets
C Bizzarri, AR Beccari, R Bertini, MR Cavicchia, S Giorgini, M Allegretti
Pharmacology & therapeutics 112 (1), 139-149, 2006
Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)
C Alfaro, A Teijeira, C Oñate, G Pérez, MF Sanmamed, MP Andueza, ...
Clinical Cancer Research 22 (15), 3924-3936, 2016
CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity
A Teijeira, S Garasa, M Gato, C Alfaro, I Migueliz, A Cirella, C de Andrea, ...
Immunity 52 (5), 856-871. e8, 2020
CXCR1/2 inhibition enhances pancreatic islet survival after transplantation
A Citro, E Cantarelli, P Maffi, R Nano, R Melzi, A Mercalli, E Dugnani, ...
The Journal of clinical investigation 122 (10), 3647-3651, 2012
Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis
S Bonini, A Lambiase, P Rama, F Sinigaglia, M Allegretti, W Chao, ...
Ophthalmology 125 (9), 1332-1343, 2018
LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells
L Sturla, C Fresia, L Guida, S Bruzzone, S Scarfì, C Usai, F Fruscione, ...
Journal of Biological Chemistry 284 (41), 28045-28057, 2009
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors
M Allegretti, R Bertini, MC Cesta, C Bizzarri, R Di Bitondo, V Di Cioccio, ...
Journal of medicinal chemistry 48 (13), 4312-4331, 2005
Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice
A Zarbock, M Allegretti, K Ley
British journal of pharmacology 155 (3), 357-364, 2008
Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury
DG Souza, R Bertini, AT Vieira, FQ Cunha, S Poole, M Allegretti, F Colotta, ...
British journal of pharmacology 143 (1), 132-142, 2004
Treatment with DF 2162, a non‐competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice
TM Cunha, MM Barsante, AT Guerrero, WA Verri Jr, SH Ferreira, ...
British journal of pharmacology 154 (2), 460-470, 2008
Targeting C5a: recent advances in drug discovery
M Allegretti, A Moriconi, AR Beccari, RD Bitondo, C Bizzarri, R Bertini, ...
Current medicinal chemistry 12 (2), 217-236, 2005
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2
A Moriconi, MC Cesta, MN Cervellera, A Aramini, S Coniglio, S Colagioia, ...
Journal of medicinal chemistry 50 (17), 3984-4002, 2007
Blockade of the chemokine receptor CXCR2 ameliorates adjuvant‐induced arthritis in rats
MM Barsante, TM Cunha, M Allegretti, F Cattani, F Policani, C Bizzarri, ...
British journal of pharmacology 153 (5), 992-1002, 2008
Lactonization of Olefins Mediated by Mn (OAc) 3: A Sonochemical Approach.
M Allegretti, A D'Annibale, C Trogolo
Tetrahedron 49 (46), 10705-10714, 1993
Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial
SC Pflugfelder, M Massaro-Giordano, VL Perez, P Hamrah, SX Deng, ...
Ophthalmology 127 (1), 14-26, 2020
Current status of chemokine receptor inhibitors in development
M Allegretti, MC Cesta, A Garin, AEI Proudfoot
Immunology letters 145 (1-2), 68-78, 2012
CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice
A Citro, A Valle, E Cantarelli, A Mercalli, S Pellegrini, D Liberati, ...
Diabetes 64 (4), 1329-1340, 2015
Carbocysteine lysine salt monohydrate (SCMC‐LYS) is a selective scavenger of reactive oxygen intermediates (ROIs)
L Brandolini, M Allegretti, V Berdini, MN Cervellera, P Mascagni, ...
European cytokine network 14 (1), 20-26, 2003
Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor
R Bertini, LS Barcelos, AR Beccari, B Cavalieri, A Moriconi, C Bizzarri, ...
British journal of pharmacology 165 (2), 436-454, 2012
The system can't perform the operation now. Try again later.
Articles 1–20